EN | RU
EN | RU

Help Support

Back

Efficacy and safety of Vonoprazan to prevent peptic ulcer recurrence in people using NSAIDs

NSAIDs NSAIDs
NSAIDs NSAIDs

A 12-month, prospective, observational, real-world study intended to evaluate Vonoprazan's safety and efficacy to prevent the recurrence of ulcers in individuals on long-term nonsteroidal anti-inflammatory drugs (NSAIDs).

See All

Key take away

Long-term administration of 10 mg Vonoprazan for up to 12 months is safe and effective to prevent NSAID-associated recurrence of peptic ulcers.

Background

A 12-month, prospective, observational, real-world study intended to evaluate Vonoprazan's safety and efficacy to prevent the recurrence of ulcers in individuals on long-term nonsteroidal anti-inflammatory drugs (NSAIDs).

Method

Examination of people with a history of duodenal or gastric ulcers who commenced using once-daily 10 mg oral Vonoprazan fumarate tablets and were taking low-dose aspirin for embolism/thrombosis suppression or NSAIDs for pain was done. In this post-marketing surveillance study, the major endpoint was adverse drug reactions (ADRs) incidence.

Result

Vonoprazan was administered to most of the individuals (86.7% [1099/1268]) for a minimum of six months. Out of 1268 patients, 98.6% patients (n = 1250) were given 10 mg Vonoprazan, 38.3% (n = 486) were given cyclooxygenase-2 inhibitors and 61.7% (n = 782) were administered other NSAIDs.

Notably, 0.71% (9/1268) was the overall occurrence of ADRs. Hepatobiliary system (0.16%), nervous system (0.16%), and gastrointestinal (0.32%) diseases were the most frequently reported ADRs. The overall occurrence of recurrence of duodenal or gastric ulcers was found to be 1.04%.

Conclusion

To prevent secondary ulcers or bleeding in individuals on long-term NSAIDs, Vonoprazan was not related to any new safety concerns. In this at-risk patient population, Vonoprazan's efficacy in preventing ulcer recurrence was validated.

Source:

Expert Opinion on Drug Safety

Article:

Long-term safety and effectiveness of Vonoprazan for prevention of gastric and duodenal ulcer recurrence in patients on nonsteroidal anti-inflammatory drugs in Japan: a 12-month post-marketing surveillance study

Authors:

Takashi Kawai et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: